Allogene Therapeutics (NASDAQ:ALLO) Releases Earnings Results, Beats Estimates By $0.04 EPS

Allogene Therapeutics (NASDAQ:ALLO) announced its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04, FiscalAI reports. The business had revenue of $4.64 million during the quarter, compared to the consensus estimate of $0.00 million.

Here are the key takeaways from Allogene Therapeutics’ conference call:

• Allogene expanded the ALPHA3 trial to more than 80 active sites ahead of schedule and now expects approximately 100 sites by year-end, supporting enrollment and broader community access to cema-cel.
• Cema-cel received FDA RMAT and Fast Track designations for first-line consolidation in MRD-positive large B-cell lymphoma, which Allogene views as validation of the unmet need and the ALPHA3 approach.
• ALPHA3’s interim EFS analysis remains expected around mid-2027 despite faster site activation; management said statistical significance at the interim point would require overwhelming efficacy.
• ALLO-316 showed a 31% confirmed response rate in CD70-high renal cell carcinoma, with durable responses among five responders, but management acknowledged the small dataset and significant safety challenges.
• Enrollment in the ALLO-329 RESOLUTION autoimmune disease trial is proceeding rapidly, with clinical and translational data—including safety, efficacy, and dose-cohort findings—expected in the fourth quarter of 2026.

Allogene Therapeutics Stock Performance

ALLO opened at $2.07 on Thursday. The stock’s 50 day moving average price is $1.95 and its 200-day moving average price is $2.12. Allogene Therapeutics has a one year low of $0.99 and a one year high of $4.46. The stock has a market cap of $714.46 million, a price-to-earnings ratio of -2.69 and a beta of 0.48.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Allogene Therapeutics during the 1st quarter valued at about $85,000. Goldman Sachs Group Inc. grew its stake in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares in the last quarter. Jane Street Group LLC increased its holdings in Allogene Therapeutics by 578.7% during the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after purchasing an additional 952,158 shares during the period. Geode Capital Management LLC raised its position in Allogene Therapeutics by 13.0% during the 2nd quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock valued at $4,289,000 after purchasing an additional 435,389 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Allogene Therapeutics by 14.0% in the 2nd quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after buying an additional 25,628 shares during the period. 83.63% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on ALLO. JPMorgan Chase & Co. raised shares of Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Thursday, April 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Allogene Therapeutics in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.52.

Key Stories Impacting Allogene Therapeutics

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cema-cel, potentially enabling more frequent regulatory interaction and an expedited review path. Allogene also plans to expand its ALPHA3 trial to approximately 100 sites by year-end, signaling an effort to accelerate enrollment and development. Allogene outlines plan for approximately 100 ALPHA3 sites and FDA grants RMAT and Fast Track
• Positive Sentiment: Allogene reported a second-quarter loss of $0.13 per share, better than the analyst consensus loss of $0.17, while revenue of $4.64 million exceeded expectations of essentially no revenue. The earnings beat may provide modest support for the shares, despite the company remaining unprofitable. Allogene second-quarter 2026 financial results and business update
• Neutral Sentiment: Management’s earnings call focused on advancing cema-cel and expanding the ALPHA3 study. These updates improve the program’s visibility, but the investment case remains dependent on clinical-trial execution, future data and regulatory decisions. Allogene Q2 2026 earnings call transcript
• Negative Sentiment: Allogene continues to report net losses and has no approved commercial product, leaving the company exposed to financing needs and the possibility of disappointing trial results. The FDA designations are not approvals and do not guarantee cema-cel’s success.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.